コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 de may serve as a marker for the severity of acute decompensated heart failure.
2 ative efficacy of UF versus standard care in acute decompensated heart failure.
3 re strategies for treatment of patients with acute decompensated heart failure.
4 and preserved ejection fraction, as well as acute decompensated heart failure.
5 those presenting with cardiogenic shock, and acute decompensated heart failure.
6 e most frequent cause for hospitalization in acute decompensated heart failure.
7 esiritide on renal function in patients with acute decompensated heart failure.
8 d not affect renal function in patients with acute decompensated heart failure.
9 ng patients hospitalized with a diagnosis of acute decompensated heart failure.
10 f, congestion, and outcomes in patients with acute decompensated heart failure.
11 chycardia (VT) in hospitalized patients with acute decompensated heart failure.
12 ndependent cohort of 75 subjects treated for acute decompensated heart failure.
13 rial-extracorporeal membrane oxygenation for acute decompensated heart failure.
14 c therapy for the treatment of patients with acute decompensated heart failure.
15 a candidate drug in clinical trials to treat acute decompensated heart failure.
16 the timing of diuretics among patients with acute decompensated heart failure.
17 8 patients (80.5%) who were hospitalized for acute decompensated heart failure.
18 adverse events in hospitalized patients with acute decompensated heart failure.
19 peptides (proBNP) in patients admitted with acute decompensated heart failure.
20 f stay and quality of care for patients with acute decompensated heart failure.
21 no impact on renal function in patients with acute decompensated heart failure.
22 ibitors that impair glucose transport induce acute, decompensated heart failure.
23 rial-extracorporeal membrane oxygenation for acute decompensated heart failure, 1-year survival was 4
24 ient mortality in patients hospitalized with acute decompensated heart failure: 4 HF-specific mortali
26 sodium nitroprusside (SNP) for patients with acute decompensated heart failure (ADHF) and low-output
27 diuresis and renal function in patients with acute decompensated heart failure (ADHF) and renal impai
29 CD-9-CM) code criteria, do not differentiate acute decompensated heart failure (ADHF) from chronic st
34 t Failure), 7,141 patients hospitalized with acute decompensated heart failure (ADHF) were randomized
35 e the in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiv
36 ion and volume overload are the hallmarks of acute decompensated heart failure (ADHF), and loop diure
40 d from admission to discharge in consecutive acute decompensated heart failure admissions (n=656).
42 worsening renal function, is also common in acute decompensated heart failure, although the definiti
43 on renal function during hospitalization for acute decompensated heart failure and associated outcome
44 esiritide on renal function in patients with acute decompensated heart failure and baseline renal dys
46 RRESS-HF) trials during hospitalization with acute decompensated heart failure and clinical congestio
47 fluid is a primary therapeutic objective in acute decompensated heart failure and commonly monitored
48 hospital practice patterns of NIPPV use for acute decompensated heart failure and their relationship
49 gulated arginine metabolism in patients with acute decompensated heart failure and to explore possibl
50 cohorts admitted to a single institution for acute decompensated heart failure and treated with UF: H
51 t Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to
52 t Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to
53 t Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to
54 t Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to
56 ardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardio
57 terogeneous nature of patients admitted with acute decompensated heart failure, and the limitations o
58 sodes of hypotension while hospitalized with acute decompensated heart failure are not well understoo
59 spital, and unplanned clinic visits to treat acute decompensated heart failure based on the blinded a
61 shock patients (acute myocardial infarction, acute decompensated heart failure, biventricular failure
62 ntial component of therapy for patients with acute decompensated heart failure, but there are few pro
63 ation should be considered for patients with acute decompensated heart failure, but timing of implant
64 e (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trials du
65 d safety of ultrafiltration in patients with acute decompensated heart failure complicated by persist
66 Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardior
68 ne the effect of tezosentan in patients with acute decompensated heart failure (HF) associated with a
69 uous ultrafiltration (SCUF) in patients with acute decompensated heart failure (HF) refractory to int
70 t, and outcomes of patients hospitalized for acute decompensated heart failure (HF) with preserved sy
72 titration of chronic oral medication during acute decompensated heart failure hospitalization may no
73 rial-extracorporeal membrane oxygenation for acute decompensated heart failure (i.e., cardiogenic sho
74 rial-extracorporeal membrane oxygenation for acute decompensated heart failure in our ICU (67% of the
75 used technology for inpatient management of acute decompensated heart failure in patients with volum
77 ss the association between air pollution and acute decompensated heart failure including hospitalisat
81 sure (SBP reduction) during the treatment of acute decompensated heart failure is strongly and indepe
84 Data from >100,000 hospitalizations from the Acute Decompensated Heart Failure National Registry (ADH
86 lysis of observational patient data from the Acute Decompensated Heart Failure National Registry (ADH
87 ts with heart failure without CRT-D from the Acute Decompensated Heart Failure National Registry (ADH
88 1 and January 2004 that were recorded in the Acute Decompensated Heart Failure National Registry (ADH
90 hospitalization episodes entered in ADHERE (Acute Decompensated Heart Failure National Registry).
91 Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-Inte
92 Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-Inte
93 We examined 196 770 AHF admissions from the Acute Decompensated Heart Failure National Registry-Unit
95 developed from 3 clinical databases (ADHERE [Acute Decompensated Heart Failure National Registry], EF
97 admission rates, morbidity, and mortality of acute decompensated heart failure, other newer approache
98 ation was then prospectively validated in 50 acute decompensated heart failure patients using meticul
99 in this population with outcomes similar to acute decompensated heart failure patients with low left
100 ients with greater iBNP levels (Registry for Acute Decompensated Heart Failure Patients; NCT00366639)
103 Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and R
105 nesiritide is approved for the treatment of acute decompensated heart failure, retrospective analyse
106 of at least 40 years and hospitalization for acute decompensated heart failure, severe systemic infec
108 domized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide
109 e cohort study of 218 patients admitted with acute decompensated heart failure to the Nashville VA Me
110 ion of oral neurohormonal antagonists during acute decompensated heart failure treatment negatively i
111 essure ventilation (NIPPV) for patients with acute decompensated heart failure was introduced almost
112 enous Pressure Measurements in Patients With Acute Decompensated Heart Failure) was a single-center p
113 f patients hospitalized for the treatment of acute decompensated heart failure will experience signif
114 in patients >/=55 years of age admitted with acute decompensated heart failure with preserved ejectio
115 ists among hospitals in the use of NIPPV for acute decompensated heart failure without evidence for d
116 ed trial involving patients hospitalized for acute decompensated heart failure, worsened renal functi
117 ndomly assigned a total of 188 patients with acute decompensated heart failure, worsened renal functi
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。